Blog
Log In
Contact us

Tag: OMNY Platform

Categories
News

OMNY Health Launches Dynamic GLP-1 Network of 600,000+ Patients to Fuel Clinical Research on Its Use

New Studies on the Use of These Medications in Adult and Pediatric Populations are Supported by the Data Network

Atlanta, Georgia – August 27, 2024 – OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data partnerships, today announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, further cementing the company’s commitment to democratizing healthcare data across industries. This new data network comprised already of over half a million patients will supply its life sciences and health system partners, as well as its AI-driven health tech partners, with additional knowledge of GLP-1 use, related social determinants of health (SDOH), and patient demographics to better inform generative AI tools, researchers, and clinicians and improve patient outcomes.

Despite a staggering amount of healthcare data being generated across health systems and life sciences companies, 97% of this data goes unused. This underutilization is particularly crucial as the usage of GLP-1 agonists surge, driven by their effectiveness in treating chronic conditions such as type 2 diabetes and obesity. The growing demand for these medications has sparked an urgent need for more comprehensive data that evaluates their effectiveness and long-term effects for other conditions like cardiovascular disease, liver disease, and skin disorders.

“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole,” said Dr. Mitesh Rao, CEO of OMNY Health. “By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.”

OMNY’s GLP-1 data network consists of curated EMR data from more than 645,000 patients representing a broad set of demographic characteristics, including age ranges, race/ethnicity, region of care delivery, as well as provider and payer types. The data network supported two recent studies that address gaps in understanding GLP-1 therapies, particularly within pediatric and patient populations impacted by SDOH factors enabling partner companies to better understand and apply findings to patient treatments.

Pediatric use of GLP-1s was not approved by the FDA until December 2022, making data on these use-cases extremely limited despite the prescriptions of GLP-1RAs for children and adolescents increasing by 594.4% from 2020 to 2023. OMNY’s GLP-1 network contains valuable information on pediatric GLP-1 use, enabling a study that found the median age of users was 16 years and the majority were female in gender (72%).

“We are able to deliver more equitable clinical outcomes when the research is backed by data from diverse populations,” said Dr. Sameer Badlani, Fairview Health Services’ Executive Vice President, and Chief Strategy Officer. “With access to data that factors in SDOH for diverse populations we learn valuable insights in service of providing resources and clinical care that is differentiated by excellence in quality, safety, experience and health equity for every consumer who trusts us with their wellness and care.”

OMNY’s network also provides critical information on SDOH factors, including economic insecurity, food insecurity, and social isolation often documented in clinician notes. With many of these factors accounting for up to 50% of the variation in health outcomes in the US, it was crucial that the SDOH status of patients receiving GLP-1 treatment be made available. A second study by OMNY found that GLP-1 patients were half as likely to have SDOH economic burden issues noted in their EHR record as compared the population of non-users.

OMNY’s data network enables companies to diversify their patient populations for clinical trials, better understand medication interactions, and strengthen treatment outcomes.

This announcement follows OMNY’s partnerships with QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and the creator of LifeSphere®. OMNY Health is committed to AI-enabled healthcare improvement and supporting research programs that aim to improve clinical care. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit www.marketing-dev.omnyhealth.com.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

Media Contact:

Chloe Fredericksdorf
omnyhealth@solcomms.co.

Categories
News

OMNY Health Launches Data Platform Designed to Power AI-Driven Health Tech Companies

OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data sharing launched its platform designed to power AI-driven health technology companies, further cementing the company’s commitment to democratizing healthcare data. QuantHealth and ArisGlobal are just two of OMNY’s newest partners to leverage this new platform to power their organizational AI-driven needs. OMNY Health’s data network uniquely addresses Generative AI’s need for large de-identified structured and unstructured electronic health record (EHR) data sets across diverse provider and patient populations, further underscoring the platform as delivering the data infrastructure and rails for provider organizations to collaborate and fuel the development and use of effective AI solutions for advancing healthcare.

“Our mission is to free data from silos, allowing it to be shared, analyzed, and morphed into life-saving treatments and better care for patients,” said Mitesh Rao, CEO, OMNY Health. “Life science organizations and providers often struggle with time and budget constraints that hinder their ability to learn from their data. Our work powering AI-driven platforms can unblock this process by partnering with AI developers with data and tools to accelerate breakthrough therapies and monitor new therapies for safety signals to ensure patient populations remain safe.”

Two of OMNY Health’s AI-driven partners being effectively powered by the platform’s data to foster new opportunities for advancing healthcare include QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®.

QuantHealth’s AI technology, trained on a dataset of 350 million patients, enhances clinical trial timelines, mitigates trial risks, and identifies populations likely to respond to treatments. OMNY’s collaboration will help QuantHealth’s pharmaceutical partners expedite drug development through simulated clinical trials, utilizing real-world evidence to predict clinical trial outcomes, drug efficacy, and patient responses.

“Biotech is entering a vibrant part of life sciences history,” said Omri Matalon, VP Clinical Data Science and Head of R&D Operations at QuantHealth. “This partnership furthers our commitment to quality data and access for our life sciences partners. By integrating diverse EHRs into organized, de-identified research data products, we can address disparities in clinical trials and close significant demographic information gaps in drug discovery and development.”

OMNY’s partnership with ArisGlobal, a leader in pharmacovigilance, safety monitoring, and reporting systems, will transform safety signal validation and pave the way for comprehensive, proactive signal detection.

“Up to 95% of adverse event cases go unreported today, while processing ICSRs can be time consuming, and analysis of medical literature and online forums is slow and inefficient,” said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. “Combining LifeSphere products with comprehensive real-time RWD addresses these challenges head-on. By leveraging advanced technology and insights from extensive RWD, we are reshaping drug discovery and development.”

These partnerships demonstrate OMNY Health’s commitment to AI-enabled healthcare improvement through acceleration of diverse participation in clinical trials and the support of research programs that aim to save lives and improve patient outcomes. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit https://marketing-dev.omnyhealth.com/.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit https://www.arisglobal.com/.

About QuantHealth

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth’s Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth’s simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/.

Categories
News Product

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

new GI real-world data solutions

OMNY Health’s GI partnerships are a pivotal step in its mission to deliver data and insights to accelerate life-changing innovation. With a focus on catalyzing research and improving outcomes, OMNY aims to make a tangible difference for the millions of individuals in the US impacted by gastroenterology diseases

ATLANTA, GA, April 22, 2024 – OMNY Health is pleased to announce its partnership with the nation’s leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY’s research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY’s real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with the health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

“United Digestive remains committed to offering our patients the most suitable and cost- effective healthcare solutions. Our dedication to delivering best-in-class GI care is intricately linked with our data-driven approach,” says United Digestive’s Chief Medical Officer, Dr. John Suh. “We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care.”

“As Florida’s leading gastroenterology provider, Borland Groover’s mission is to provide exceptional care and improve the lives of our patients. Achieving this objective requires a deep understanding of our patients, patterns of care, outcomes, and opportunities for further improvement through data analysis,” said Borland Groover’s CEO, Dr. Kyle Etzkorn. “Our collaboration with OMNY not only aligns with our mission, but it also presents avenues to identify and pursue future opportunities for elevating GI patient care.”

“Enhancing patient care isn’t just a goal; it’s our responsibility, guided by the personal experiences of every patient we serve. Each piece of patient data is not just a statistic; it is a pathway to better outcomes, a testament to our commitment, and a source of inspiration for ongoing progress” said Christa Newton, MBA, CEO, OneGI. “We are excited to partner with OMNY as a tangible step in realizing these guiding principles for the benefit of our patients.”

“It is important to One GI that our patients are represented when it comes to emerging research, care improvement initiatives, and best in class care. Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy to access exceptional GI care.” – Dr. Michael Dragutsky, Founder, Chairman, OneGI. Key populations available in the GI specialty offerings are aligned with the significant research and development efforts underway in gastroenterology, including ulcerative colitis, Crohn’s disease, celiac disease, short bowel syndrome, reflux disorders, and many others. Like other OMNY Health specialty-focused solutions, the GI offering includes information covering pharmacy orders, lab and diagnostic test results, comorbidities, symptom checklists, and provider clinical assessment scores. “We are thrilled to welcome our new gastroenterology providers to our network. Over the past two years, we have made great strides connecting researchers and providers participating in our dermatology and ophthalmology research networks. We look forward to building on that impact in the field of gastroenterology,” said Mitesh Rao, MD, CEO, OMNY Health.

About OMNY Health

OMNY Health connects the healthcare ecosystem through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs.   The OMNY platform serves as a centralized resource for healthcare stakeholders to participate in data sharing and research services at scale, fueling innovation where patients need it the most. For more information, go to www.marketing-dev.omnyhealth.com.

MEDIA INQUIRIES: media@omnyhealth.com 

Categories
Editorial

Linking Real-World Clinical Data with Medical Device Data to Demonstrate Device Value

Clinical Data, Medical Device

Real-World Data in the Medical Device Market

Many life sciences organizations are focused on harnessing real-world data (RWD) capabilities to inform every part of the drug development product life cycle. The same types of RWD can, and should, be applied to innovation around the development and measurement of the effects of medical devices. RWD derived from healthcare sources, such as electronic health records, provides insights into the burden of disease, and after a device market launch, provides insights into competitive stance, safety, efficacy, and outcomes. Traditionally, these types of analyses have been difficult to perform for medical devices because the specific details surrounding the medical device make, model, and manufacturer used in procedures are often buried in the electronic health record or other IT systems, and historically have not been collected uniformly. 

Medical Devices in the Real World

Medical Devices have become a critical part of a patient’s daily life, and how patients interact with these devices can tell us a lot about their effectiveness. From joint replacements to life-saving arterial stents and pacemakers, device manufacturers are interested in the benefit-risk profiles to inform future device modifications and technological advancements, Providers can glean important evidence for the clinical effectiveness of these devices, helping to inform what devices to use in their procedures. 

Medical device manufacturers are motivated to invest in new strategies to support success. According to McKinsey, despite a period of growth from 2012 through 2019, S&P medical device investments slowed during the pandemic. Recently, however, signs have been promising; in 2023, the U.S. approved more novel medical technologies than in any single year before, and revenue growth rates are starting to stabilize to pre-pandemic levels. 

Aggregation of RWD to Inform Device Safety and Evidence for Effectiveness

Using relevant and reliable RWD is important for generating RWE to understand and regulate medical device usage and safety. To get a complete picture of the patient’s use and interaction with a medical device, RWD from clinically relevant sources is required to give a holistic view of the clinical experience both before device implant/initiation and after usage has been initiated. The ability to combine disparate data from multiple sources and care settings is where OMNY Health excels. 

The OMNY Health Medical Device Data Advantage

OMNY Health’s Medical Device product offering is a best-in-class view into the healthcare industry’s use of medical devices in patients. Our Medical Device offering is constructed directly from our health provider data sets, with precision down to the patient encounter level. Utilizing the Unique Device Identifier (UDI) and the device version, we have partnered with the FDA’s AccessGUDID database to ensure the highest quality and completeness of data, with unrivaled recency. 

OMNY Health’s Medical Device product offering linked with OMNY Health’s EHR data, can help device manufacturers and provider networks better understand and assist the patients they are servicing by examining: 

  • Medical Device use and trends 
  • Patient journeys and continuity of care
  • Impact of medical devices on clinical, functional, cost, and utilization outcomes
  • Safety/adverse event reporting
  • Providers who are interested in value-based contracting and making procurement decisions

Check out the Total Knee Replacement study utilizing the OMNY Health Medical Device product offering. 

Contact OMNY to learn more about how our Medical Device product offering will boost your real-world evidence generation.

Categories
Editorial

Social Determinants of Health: Generating Accurate Clinical Insights Using Real-World Data

Social Determinants

Recent innovations in healthcare analytics and patient-oriented AI demonstrate the power of leveraging real world data (RWD) to generate ecologically valid actionable insights for life sciences companies to improve patient lives and streamline new therapeutic advances. Such insights are essential for decision-making in health economics and outcomes research (HEOR) and in the clinical trial planning and implementation processes. However, the breadth, depth, and inclusivity of the data used to generate such insights can have a huge impact on both the accuracy and validity of any analyses. Various sources of bias, such as the lack of demographic and socioeconomic diversity in a cohort, can undermine the main benefit of using RWD to supplement life sciences research. To combat this, many researchers and providers have publicized the need for clinically-validated metrics that can be used to measure and quantify cohort-level bias and provide more transparency in the field.

Social Determinants of Health Data Account for Notable Variations in Clinical Outcomes

One commonly referenced set of measures that has received growing recognition is social determinants of health (SDoH) data – a set of criteria used to capture economic and social vulnerabilities across key domains. Various studies have estimated that accounting for SDoH variables, such as income level, housing security, transportation, gender identity, and race and ethnicity, can account for 40 – 60% of the variation in clinical outcomes and care patterns. A recent study examining Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) data illustrates this all too well. Researchers found that trial participants in the lowest-income trial sites had poorer blood pressure control and worse outcomes for some adverse cardiovascular events, even when treatment access and adherence were accounted for. The authors concluded that these results clearly illustrate “the importance of measuring and addressing socioeconomic context in [randomized controlled trials] RCTs.” The incorporation of these factors into studies leveraging RWD is just as important.  

United States Government Support for Clinical Research and RWD Inclusivity

Researchers are not the only ones promoting the importance of SDoH – the U.S. government is facilitating efforts to foster greater inclusivity in clinical trial participation across multiple fronts. The Food and Drug Administration has issued new guidelines about the use of RWD in clinical research, pointing to the utility of inclusive data sources to identify clinical trial participants. The Centers for Medicare & Medicaid Services (CMS) are also focused on health equity. At the end of 2023, CMS released an updated framework for health equity with a focus on the collection of interoperable, standardized SDoH. As of January 2024, CMS requires the screening of five SDOH domains for admitted hospital patients.  

Challenges with Obtaining and Utilizing SDoH Data

Despite the power of SDoH to create a more inclusive real-world environment for clinical trials and research analyses, patient-level SDoH data availability to pharmaceutical companies has been lacking. This is in large part due to barriers relating to extracting and aggregating relevant material. In typical healthcare systems, patient-level SDoH data are often difficult to expose and curate as the relevant information is buried in clinical codes and unstructured notes. However, the aforementioned efforts by various government entities have resulted in an exponential increase in the amount of patient-level SDoH data available in medical records – including increased use of structured surveys and other collection tools. 

Much of the SDoH data currently available in the RWD marketplace rely on a combination of 3-digit zip-code-level data and aggregated claims or credit data, which only provide inferred modeled proxies, not insight into actual patient-level information. Those that are able to derive SDoH variables through direct access to EHRs often face issues such as data lags, inconsistent data collection vehicles, and gaps in reporting. OMNY Health has the technology in place at the provider level creating a direct flow of data through the OMNY platform so that data is captured consistently with limited lag time. These unique integrated partnerships with large integrated delivery networks (IDNs) and specialty networks have enabled us to quickly capitalize on the growing availability of SDoH data in patient records.  

OMNY Health Top-tier SDoH Data Sets

OMNY Health is focused on creating a best-in-class SDoH data product to augment our existing EHR-derived, de-identified clinical data sets. Our ​​Social Determinants data offering is constructed from point-of-care documentation aggregated at the patient-encounter level. To ensure deep, multi-faceted coverage, we leverage multiple streams of information, including ICD-10 diagnostic codes, self-reported responses to standardized SDoH surveys, and estimated SDoH burden derived using research-grade, validated NLP models run on unstructured clinical notes.  

OMNY Health’s Social Determinants data offering, when integrated with our extensive clinical data sources, can help pharmaceutical companies and provider networks better help the patients they are serving and be more successful by informing: 

  • More accurate HEOR analyses 
  • Inclusive clinical trial planning and implementation 
  • Analysis of clinical trial results and differences in real-world populations 
  • The development of precision medicine treatments 
  • The understanding of the barriers to drug access and adherence and how to develop targeted programs to reduce those barriers 
  • Different disease severity and outcomes across populations and geographies 
  • Market access and pull-through strategies for contracting and drug promotion. 

SDoH data can offer insight into the everyday non-clinical factors that influence how individuals develop diseases, respond to treatments, and participate in clinical trials.  

Contact OMNY to learn more about how our SDoH data sets will boost your real-world evidence generation.

Categories
Editorial

Five Strategies To Boost Clinical Trial Diversity

Five Strategies To Boost Clinical Trial Diversity
Categories
Editorial

Looking Back and Looking Forward: Top Five’s for 2021 and 2022

Happy New Year! We hope your family had a safe and healthy holiday season. 2021 was a busy year for us at OMNY Health, and we made great strides toward building out our ecosystem and supporting our mission of accelerating clinical innovation. To hit the highlights, we’ve put together two Top 5 lists, reminiscing some of our top 2021 achievements and looking ahead at some of the exciting opportunities coming in 2022.

Top 2021 Achievements

Commercial Launch of the OMNY Health Platform

In May, we announced the commercial launch of the OMNY Health Platform, a platform that endeavors to bring together the healthcare ecosystem, centered around data-driven clinical innovation. Since our launch, we have greatly expanded our commercial pipeline with a number of buyers actively evaluating our data offerings and utilizing our platform.  

Successful Completion of SOC 2 Type 1 Certification

In addition to our May product launch, we also achieved SOC2 Type 1 certification that same month. To achieve this our compliance and dev ops teams worked hard to put 25 policies and 90 related controls in place in the first part of the year. Being SOC2 compliant assures our partners that we have the infrastructure, tools, and processes to protect their data and to ensure that organizational controls and practices effectively safeguard the privacy and security of OMNY Health and partner data.  

Massive Integrated Dermatology Data Repository

One month later, we followed our commercial launch with the announcement of our national dermatology data repository. Initially launched with 7.5M+ patient lives, our overall data set now covers 40 of the 50 states, representing 22M+ patient lives, and includes care provided by over 47,000 providers. This represents nearly an 8x growth year over year in our data partnerships. In addition to our Base EHR data offering, we recently launched a product containing Surveys, Questionnaires, and Scores data. This unique offering sets us apart from other vendors, allowing researchers to capture outcomes values provided by providers and patients.  

Research Driven Support for Clinical Innovation

Our biostatistics/data science team has been deep in research mode all year. They have presented over a dozen posters and oral presentations at a number of large conferences this year, including ISPOR Europe, John Snow Labs NLP Summit, ISPE 37th International Conference, DIA Global Annual Conference, and ISPOR Annual Conference. All research has been based on data from our data repository and is helpful to demonstrate the value and utility of the data offerings we provide to customers. These presentations have broached an expansive cross-section of topics from COVID-19 to dermatology to natural language processing (NLP). And despite the holidays, our team spent much of the last few weeks in December hard at work drafting ten submissions for 2022’s ISPOR Annual Conference. 

Strengthened Intellectual Property Portfolio

In addition to one patent that was granted in 2020, we have two new patents that were granted in 2021. The patents granted were Unbiased Drug Selection using Distributed Ledger Technology (US 11,093,552) and Private Currency and Trade Engine (US 11,094,013). We are proud of our innovation team for getting these patents granted.  

Top 2022 Opportunities

Orthopedic and Ophthalmology Data Repository

We’ve been busy signing a number of orthopedic and ophthalmology practices to increase the patient lives and type of data covered in our data repository. Similar to how we built our large dermatology repository in 2021, we expect our numbers in orthopedics and ophthalmology to rival our dermatology data by mid 2022. In addition, we’ve been growing the number of signed health systems and will have broader coverage across additional service lines and specialties coming as well. 

Rapidly Expanding Team

We are growing, and we are hiring! In the last half of 2021, we saw our technical teams double in size, and we expect to almost double in all departments across the board in 2022. We are looking for talented and experienced people who can hit the ground running. We have a number of open roles available on our careers page  and invite you to please send good people our way.  

PandemicX Cohort

In December, we announced that we are one of the fifteen health tech startups accepted into the 2022 PandemicX Cohort. We will be working closely with U.S. Department of Health and Human Services and Mass Challenge Health Tech to use data to help solve the problems of health equity that have been brought to light by the pandemic. This aligns well with our mission, and we cannot wait to get started on this project. 

Data Expansion

In 2021, the introduction of our EHR data sets allowed us to become a major player in the industry. In 2022, we hope to expand those data sets even more with the addition of claims data. The augmentation of EHR data with claims data expands the opportunities and types of studies for which our data can be used. Throughout 2021, we have been building our capabilities for using natural language processing (NLP) to extract structured fields from unstructured notes data. This coming year, we expect to refine our processing and productize much of this data. 

Insights Beyond the Data

In the coming year, our roadmap includes a number of reports and dashboards that take a step beyond just data and into the realm of insights. We have been working closely with both sides of our ecosystem on some beta products that will allow users to make faster, more data-driven decisions. 

As you can see, we did some BIG things in 2021, but have even BIGGER things coming in 2022. Thank you to all of our partners, investors, and customers for your collaboration and support. We could not be where we are today without your help. And we look forward to continuing to build on these relationships in the coming year. Cheers to all the things to come in the New Year!

About the Author:
Dr. Mitesh Rao is the Founder and CEO of OMNY Health. A Board-Certified Emergency Medicine Physician, Dr. Rao has held executive roles at both Stanford’s and Northwestern’s health systems, where he helped lead patient safety and innovation. As a physician leader and executive, he has helped implement systems-level improvements for quality and safety in institutions across the country and overseas that have had lasting effects on care provision. Throughout his career, Dr. Rao has helped implement and scale new technologies within the clinical venue and serves as a mentor to multiple startups and accelerator groups across the country in order to help guide the development of innovative solutions that can sustainably impact patient care.

Categories
News

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

Dover, DE and Atlanta, GA. Oxford, U.K. October 13, 2021: Sensyne Health plc (LSE: SENS) (“Sensyne”), the ethical Clinical AI company, and OMNY Health (“OMNY”), a leading US-based real world data company, today announced a strategic teaming relationship.

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research.

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said:

“This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said:

“OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”
Sensyne is working with life science partners on different types of research projects across multiple disease areas. The actionable insights from OMNY’s longitudinal patient data sets will help them with synthetic control arms, patient stratification, patient identification and selection, plus important late-phase clinical trial design, commercialisation, and health economic pricing decisions.

For more information email: lifesciences@omnyhealth.com.

Categories
News

OMNY Health Launches Massive Integrated Dermatology Data Repository and Research Network to Advance Life-Changing Innovations for Patients Suffering from Skin-Related Conditions

ATLANTA, June 23, 2021 /PRNewswire/ — OMNY Health (OMNY Inc.) is pleased to announce it has partnered with the nation’s leading community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research.

The assembled longitudinal data represents care delivered over the past five years by over 1,000 dermatologic providers in more than 30 states, across more than 7.5 million unique patients. OMNY Health works with providers to integrate and standardize their siloed disparate EHR data, enabling the delivery of de-identified data into research-ready subscriptions for Life Sciences organizations, while also delivering insights based on the normalized data back to the data contributors.

At the core of the OMNY Health platform is de-identified, normalized EHR data, further enhanced with tokens that support linkages to data derived from administrative claims, registries and other data resources, while maintaining patient anonymity. OMNY Health leverages natural language processing (NLP) technology to analyze unstructured data to derive insights often buried in clinician notes, such as adverse drug events, social determinants of health, and reasons for therapy changes.

“We are excited to partner with these forward-thinking dermatology providers to launch OMNY Health’s first suite of specialty databases. As the number of specialty treatment options expands, OMNY Health provides an ideal platform for delivering scalable data solutions to life sciences companies needing to understand the care delivered by the diverse mix of providers treating patients along their care journey. Data available on the platform provides the information needed to better understand the patient and provider landscape, design and identify eligible patients for trials, monitor the impact of launch of new therapies in the real-world setting, and evaluate safety and effectiveness of those therapies”, said Dr. Mitesh Rao, CEO at OMNY Health.

Investment in dermatology has experienced double-digit growth over the past several years and is expected to continue to grow, particularly for the conditions falling at the intersection of inflammatory and autoimmune skin disorders, such as alopecia areata, psoriasis, and atopic dermatitis. “We can now address the retrospective and prospective data and analytic needs of life sciences organizations working on treatments for some of the rarest dermatologic conditions, such as epidermolysis bullosa and generalized pustular psoriasis, to common conditions such as acne, and everything in between,” said Stacey Long, Chief Strategy Officer, who oversees OMNY Health’s product and data science teams.

“Advanced Dermatology and Cosmetic Surgery, the nation’s premier dermatology practice, values our partnership with OMNY. As we actively explore cutting edge therapeutics and leverage our robust data set to find ways to best serve our patients and the dermatology community, a collaboration with an advanced partner, like OMNY is crucial to our long-term success.” Allison W. Lynch, Chief Operating Officer, Clinical Research

“We are excited to partner with OMNY Health in looking at real world data. It’s an invaluable resource that creates improved patient outcomes, quality metrics, cost efficiencies, and tools for evaluating best practice opportunities. It also allows for prospective research to evaluate new ideas, therapies, and measurement tools that can assist in making better decisions for patients, physicians, payers, and the industry,” said Dr. Mark Jackson, Clinical Professor of Dermatology, University of Louisville and Director of Medical/Clinical Research, Forefront Dermatology.

Dr. Jackson will join Lawrence Rasouliyan, OMNY Health’s Head of Biostatistics and Data Science, on June 24, for a webinar discussion on the vital role of physicians in supporting real-world evidence generation in dermatology and the transformative opportunity for patients, providers, and life sciences organizations. Register at https://marketing-dev.omnyhealth.com/events-webinars/register-for-webinar-real-world-data-in-dermatology-why-it-matters/

About OMNY Health

OMNY Health connects patients, providers, and life sciences companies through data and insights to transform healthcare delivery, improve clinical outcomes, and address patient’s unmet needs. For more information, go to www.marketing-dev.omnyhealth.com or email: lifesciences@omnyhealth.com.

View full press release

Categories
Product

Accelerate the Pace of Life-Changing Innovation

Hidden deep in healthcare data lies powerful insights and clinical revelations. Knowledge, that when shared with healthcare visionaries, can spark actions that will accelerate the pace of life changing innovations.  Curating this wealth of knowledge requires precise data handling and a sharp focus on balancing two important factors:  Patient Privacy and Care Innovation.  

OMNY Health’s technology solutions deliver immediate value to Life Sciences researchers by delivering standardized patient, encounter, notes, and supply data from a diverse set of providers in a secure cloud platform. With off-the-shelf data, dashboards, reports, and analytics available in a variety of formats and combinations, time to insights and decisions accelerate, so your team can focus on improving access to effective treatments and transforming the lives of patients. OMNY works closely with integrated delivery networks, community hospital systems, and even specialty practices to harmonize their data, enable custom analytics and create a real-word data pipeline. 

These clinical insights are shared with Life Sciences companies for use in expediting Research & Development, driving new therapy launches and accelerating commercialization strategies. And while providers and pharmaceutical innovators benefit significantly from the standardization and flow of useful data, the ultimate winners are the patients.

Here’s an example:

Working with 2 health systems, we uncovered insights that directly informed treatment decisions for Myasthenia Gravis, or MG, patients and powered pre-launch research for a new innovative MG drug . What’s more, we provided real-world context to understand MG therapy burden and barriers to care.

Healthcare data holds the promise of clinical innovation. OMNY can connect you with the quality data you need to inform and transform actions that will make a real difference in patients’ lives. The future of healthcare is accessible today.

 To learn more about this story and how to partner with OMNY Health, please contact us.